Media Newsroom of

Philogen S.p.A.

Philogen S.p.A.

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders.

Philogen Announces Publication of Malignant Brain Tumor Study Results in Science Translational Medicine

Philogen Announces Publication of Malignant Brain Tumor Study Results in Science Translational Medicine

Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce the publication of a peer-reviewed scientific article in Science Translational Medicine. The article is entitled: "Immunocytokines are a promising immunotherapeutic approach against glioblastoma” (T. Weiss, E.…

Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer

Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer

Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that the Swiss national competent authority Swissmedic issued the authorization to run a clinical phase II study in patients with locally advanced, not metastatic nonmelanoma skin cancer. A favorable opinion about…

Philogen Received Combination Pack Approval for Nidlegy

Philogen Received Combination Pack Approval for Nidlegy

Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that, on Jan. 30, 2020, EMA's CHMP expressed a favorable opinion to the request of a combination pack for the to-be-marketed pharmaceutical form of NidlegyTM, a combination of the active principles…

Philogen Receives Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma

Philogen Receives Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma

Philogen S.p.A., a clinical-stage biotechnology company focused on discovering and developing innovative immunology and immuno-oncology protein therapeutics, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation status to Fibromun for the treatment of soft tissue…

Philogen and The Scripps Research Institute Announce Research Collaboration in the Field of DNA-Encoded Chemistry

Philogen and The Scripps Research Institute Announce Research Collaboration in the Field of DNA-Encoded Chemistry

Philogen S.p.A., a privately owned company, and Scripps Research Institute, a nonprofit American medical research facility that focuses on research and education in the biomedical sciences, today announced a research collaboration to discover new small molecule-based therapeutics using Philochem’s proprietary…

Philogen Announces the Authorisation of a Clinical Trial With Phc-102 for the Imaging of Renal Cell Carcinoma

Philogen Announces the Authorisation of a Clinical Trial With Phc-102 for the Imaging of Renal Cell Carcinoma

Philogen S.p.A. (www.philogen.com) announced today, that an exploratory clinical study involving PHC-102, a 99mTc-labeled small molecule ligand of Carbonic Anhydrase IX (CAIX) for the non-invasive detection of renal cell carcinoma and other CAIX-expressing tumors, was authorised by the Austrian competent…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login